One of the reasons biotech stocks can be your portfolio’s biggest winners is because of the massive profits companies see after releasing a blockbuster drug – especially with the exorbitantly high prices of this year’s new treatments.
invest in biotech stocks
- These Biotech Stocks Are Tied to the World’s Most Expensive New Drugs
- Stocks to Buy: Intercept Pharma (Nasdaq: ICPT) Ready to Double
- The Secret to Making Money from Bioscience's "Scariest Event"
- How to Spot Biotech Shares with “Blockbuster” Potential
- Best Stocks to Buy Now: A Hot Biopharma, an Energy Sector Worth $2 Trillion, and More
- Stocks to Buy: Why This Biopharma Company Is a “Long-Term Profit Machine”
- Stocks to Buy: This Botox Competitor Is Heading Toward Huge Profits
- There Is No Biotech Bubble; Here's the Real Story
- Finding the Blockbuster That Will Make You Rich
- The Secret Behind This Controversial Industry's Leader
- Double Your Money with Our "High-Tech GPS"
- Three Bioscience Breakthroughs You Can't Afford to Miss
- Penny Stocks to Watch
- Penny Stocks: Today's Biggest Movers
- Investing in Tech: We Sure Hope You Own These Three "Wealth Building Blocks"
- Bypass These Pitfalls to (Major) Profits in Bioscience
Usually the best stocks to buy have not already tripled in value within the past six months.
But then there's Intercept Pharmaceuticals Inc. (Nasdaq: ICPT).
This biotech stock soared more than 500% in two days on the news its innovative and promising hepatitis drug obeticholic acid, or OCA, had a trial stopped early because the drug met the goals of the study.
Bulls have refused to be distracted by some negative news that has pushed the stock back under $300 in the meantime.
In bioscience investing, binary catalysts are milestone events that signal a thumbs-up or thumbs- down for an experimental drug as it makes its way through the regulatory process.
Positive catalysts can send a share price soaring. Negative ones can send it into a nosedive.
Perhaps the least understood of these catalysts are FDA Advisory Committee (a.k.a. AdCom) recommendations.
But they're also among the most powerful.
Here's what I mean, and how to play them profitably... Full Story
The FDA's Expedited Programs help get promising new therapies for seriously ill patients approved as soon as possible.
But they also create an unintended side effect that's a huge advantage for investors: They point exactly to the biggest money-making opportunities in the bioscience industry.
They're like big, green, neon signs that say, "This is an important drug with incredible profit potential."
And this is how you find them... Full Story
Our roundup of the best stocks to buy last week gave Money Morning Members more than a dozen plays in 2014's most profitable sectors.
One pick involves a possible healthcare merger that would combine two industry titans. The duo would create an industry powerhouse with a market cap near $300 billion. Another play revolves around one of the most highly anticipated, and possibly biggest, initial public offerings ever. And a special report from our small-cap trading specialist showed readers a technique for uncovering investment winners today.
One strategy experts use when looking for the best biotech stocks to buy is finding companies with promising drug candidates that are close to receiving regulatory approval. When these drugs hit the market, they can bring in billions in revenue.
When companies have multiple promising drugs in their product pipeline, they become even more attractive because they have more than one shot at finding a revenue blockbuster.
When Valeant Pharmaceuticals International Inc. (NYSE: VRX) and activist investor Bill Ackman made an unsolicited $46 billion bid to purchase Botox maker Allergan Inc. (NYSE: AGN) last week, investors got a glimpse of just how big the Botox market is globally.
And that had us pointing to our "Stocks to Buy" list...
<strong><em>Money Morning</em></strong>'s Defense & Tech Specialist Michael A. Robinson has been recommending a biotech stock that develops similar specialty products for dermatological applications. And it could see huge gains soon...
Some analysts feel that the biotech sector's recent tumble is evidence of the biotech bubble bursting.
But they're wrong; the market is simply in a period of adjustment.
The premise behind the bubble idea is that biotech companies as a group are overvalued, that their market caps aren't supported by performance. In other words, that their perceived value is all smoke and mirrors.
In the pharmaceutical industry, a "blockbuster" is any drug that brings in $1 billion or more in revenue per year.
It's the prize that every biotech hopes to win - and every biotech investor hopes to cash in on.
So how do you spot one in the making? If the market suspects a drug candidate has blockbuster potential, catalysts (events like positive clinical study results and regulatory milestones) will give its manufacturer's share price a big, big boost.
There is no crystal ball that's 100% accurate when experimental drugs are concerned, but here are some telling questions that can narrow your search...
As a long-time tech-investing analyst, I have one of the best vantage points in the country for tracking profitable marijuana industry trends.
Here's the thing: I live 10 minutes from the epicenter of the medical marijuana movement in northern California, and the rest of the nation for that matter.
Downtown Oakland contains a small cannabis-friendly district known as "Oaksterdam." In fact, there's a patient co-op across the street from a store where I buy my fedoras.
I bring all this up so you know I've followed what's been happening with the marijuana legalization movement for years.
In these parts, it's difficult to avoid - you see lots of folks walking around wearing their official Oaksterdam t-shirts.
Since California legalized medical marijuana in 1996, another 19 states have joined the movement.
The San Francisco-based market research firm ArcView Group estimates the national legal marijuana market at $1.53 billion in 2013. ArcView expects sales to nearly double to $2.57 billion by the end of this year.
Early last year, I saw a research study that said nearly 60% of all U.S. workers have a net worth of less than $25,000.
And that means they have no retirement.
From the moment that I saw that research, I knew I had a mission - to help folks reclaim their financial futures by breaking free of Wall Street's self-serving shackles... and creating wealth all on their own.
And I knew there was one avenue to travel - the high-tech highway.
So I developed a roadmap - a set of five rules - that would serve as a kind of "tech-investing GPS." My goal was to help investors identify "double-your-money" tech stocks - and navigate their way to massive high-tech wealth.
Today I'm going to walk you through those rules again, and also give you a bonus - a biotech stock with double-your-money potential.
You can make huge gains investing in a breakthrough drug, but you can do even better putting your money into a new, cutting-edge technology platform that can fuel a company's entire pipeline.
One biotech I recommended to my BioScience Millionaire subscribers last July, Sangamo Biosciences Inc. (Nasdaq: SGMO), has developed a technology from naturally occurring molecules, called zinc finger proteins (ZFPs), that scientists can engineer to edit specific genes in the human genome. It can cut them out, replace them, or add new ones - in other words, it plays with the basic building blocks of life as if they were Lego pieces!
Sangamo is currently using ZFP technology to find cures for some of the most intractable - and often un-druggable - diseases we know of, including HIV, Alzheimer's, Huntington's, and Down's syndrome to name a few.
And Sangamo isn't the only company using ZFPs for research. In fact, it licenses out the technology to scientific institutions and companies all over the world - providing it with a great revenue stream.
As a result, SGMO shares have gone up more than 150% since last summer. Actually, if you'd had the foresight to buy the stock at the beginning of 2012, you'd now be realizing profits of 577% on your money.
The magic word in that sentence is "foresight." The trick is to spot these technologies early in their development, either before they've had IPOs or soon after.
With that in mind, here are a few exciting new technologies to keep an eye on... Full Story
The recent spate of uninspiring data, from unemployment to retail sales, has been blamed on the unrelenting cold and snowy winter. But one group that hasn't been affected, and isn't using the convenient "bad weather" excuse, is this list of penny stocks to watch now.
This week brought huge gains from several low-priced stocks across all sectors:
A number of penny stocks showed investors some love today (Friday) with huge share-price climbs.
While the Dow Jones Industrial Average rose just under 1% by 2 p.m., these hot penny stocks were up double digits.
I get a lot of questions from you folks here at the Strategic Tech Investor.
And the single most frequently asked query is this one:
"Michael, what's the best way to get started as a tech investor?"
I'll grant you: As questions go, that's probably the most basic one that you'll find.